Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

LPCN

Lipocine Inc

Last Close
May 09 • 04:00PM ET
5.24
Dollar change
+0.39
Percentage change
8.04 		%
Held by: VTI VXF DFAT
Index- P/E- EPS (ttm)-3.15 Insider Own3.03% Shs Outstand5.32M Perf Week11.49%
Market Cap28.03M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.19M Perf Month-19.51%
Income-16.35M PEG- EPS next Q-0.62 Inst Own8.91% Short Float5.36% Perf Quarter30.67%
Sales0.11M P/S254.85 EPS this Y52.70% Inst Trans-63.19% Short Ratio4.18 Perf Half Y107.94%
Book/sh3.83 P/B1.37 EPS next Y- ROA-54.02% Short Interest0.28M Perf Year23.29%
Cash/sh4.12 P/C1.27 EPS next 5Y- ROE-58.40% 52W Range2.31 - 7.15 Perf YTD87.81%
Dividend Est.- P/FCF- EPS past 5Y19.47% ROI-80.28% 52W High-26.71% Beta1.07
Dividend TTM- Quick Ratio8.69 Sales past 5Y-67.27% Gross Margin73.94% 52W Low126.83% ATR (14)0.43
Dividend Ex-Date- Current Ratio8.69 EPS Y/Y TTM-50.27% Oper. Margin-13610.84% RSI (14)56.18 Volatility7.50% 9.28%
Employees17 Debt/Eq0.00 Sales Y/Y TTM-78.00% Profit Margin-14867.29% Recom1.00 Target Price33.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-0.82% Payout- Rel Volume0.67 Prev Close4.85
Sales Surprise- EPS Surprise196.75% Sales Q/Q- EarningsMay 09 BMO Avg Volume66.54K Price5.24
SMA204.55% SMA5011.71% SMA20040.69% Trades Volume44,814 Change8.04%
Date Action Analyst Rating Change Price Target Change
Jun-24-21Initiated Cantor Fitzgerald Overweight $3
Dec-10-20Upgrade Ladenburg Thalmann Neutral → Buy $3
Jan-12-18Reiterated H.C. Wainwright Buy $10 → $3
Jan-11-18Downgrade Canaccord Genuity Buy → Hold $11 → $2
Dec-08-17Resumed H.C. Wainwright Buy $10
Oct-07-16Initiated H.C. Wainwright Buy $25
Jul-22-15Initiated ROTH Capital Buy $36
Jun-23-15Initiated Canaccord Genuity Buy $15
Today 01:53PM
LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024
(InvestorPlace) +8.04%
08:00AM
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
(PR Newswire)
06:24AM
Lipocine: Q1 Earnings Snapshot
(Associated Press Finance)
May-08-24 08:00AM
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
(PR Newswire)
May-01-24 08:00AM
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
(PR Newswire)
07:00AM Loading…
Apr-11-24 07:00AM
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
(PR Newswire)
Mar-28-24 08:00AM
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
(PR Newswire)
Mar-25-24 08:00AM
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
(PR Newswire) +8.91%
Mar-07-24 02:52PM
LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023
(InvestorPlace)
08:00AM
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
(PR Newswire)
Mar-06-24 08:00AM
Lipocine to Present at 36th Annual Roth Conference
(PR Newswire)
Feb-06-24 08:00AM
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
(PR Newswire)
Feb-02-24 08:00AM
Lipocine Announces Continued Commercialization of TLANDO through Verity Pharmaceuticals
(PR Newswire)
Jan-18-24 08:00AM
Lipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the U.S. and Canada
(PR Newswire)
Dec-19-23 08:00AM
Lipocine to Present at Biotech Showcase 2024
(PR Newswire) +11.41%
02:45PM Loading…
Nov-13-23 02:45PM
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting 2023
(PR Newswire) +11.20%
Nov-08-23 08:17AM
Lipocine: Q3 Earnings Snapshot
(Associated Press Finance)
08:00AM
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
(PR Newswire)
Nov-01-23 08:00AM
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting 2023
(PR Newswire)
Oct-26-23 08:00AM
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
(PR Newswire)
Oct-23-23 07:00PM
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
(PR Newswire)
Sep-19-23 04:05PM
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
(PR Newswire)
Aug-16-23 06:02AM
LPCN: Trial Results Improve Outlook
(Zacks)
Aug-10-23 08:09AM
Lipocine: Q2 Earnings Snapshot
(Associated Press Finance)
08:00AM
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
(PR Newswire)
Jul-31-23 06:13AM
LPCN: 1148 Shows Muscle Loss Reversal
(Zacks)
Jul-27-23 06:30AM
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
(PR Newswire) +18.60%
Jun-14-23 08:00AM
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
(PR Newswire)
Jun-07-23 08:00AM
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
(PR Newswire)
May-19-23 09:14AM
LPCN: 1154 Results Illuminate Accelerated Pathway
(Zacks Small Cap Research)
07:00AM Loading…
May-16-23 07:00AM
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression
(PR Newswire) -17.72%
May-11-23 06:23AM
Lipocine: Q1 Earnings Snapshot
(AP Finance) +7.30%
06:00AM
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023
(PR Newswire)
Apr-03-23 08:00AM
First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154
(PR Newswire)
Mar-16-23 06:00AM
LPCN: 2022 Operational & Financial Update
(Zacks Small Cap Research) +9.55%
Mar-10-23 08:30AM
Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock
(PR Newswire) -26.79%
08:30AM
Lipocine Announces Financial Results for the Year Ended December 31, 2022
(PR Newswire)
Jan-16-23 08:06AM
Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
(Simply Wall St.)
Jan-05-23 08:00AM
Lipocine to Present at Biotech Showcase
(PR Newswire)
Dec-19-22 08:00AM
Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis
(PR Newswire) +5.62%
Nov-30-22 04:28AM
LPCN: Focus on CNS Disorders
(Zacks Small Cap Research)
Nov-09-22 08:00AM
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022
(PR Newswire) -5.98%
Nov-03-22 08:00AM
Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline
(PR Newswire)
Oct-11-22 08:00AM
Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference
(PR Newswire)
Sep-27-22 01:21PM
Lipocine to Participate in the Cantor Neurology & Psychiatric Conference
(PR Newswire) -11.85%
Sep-26-22 11:39AM
Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets
(Benzinga) -10.41%
08:00AM
Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders
(PR Newswire)
Sep-22-22 04:10PM
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference
(PR Newswire)
Sep-15-22 08:00AM
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)
(PR Newswire) +5.69%
Aug-10-22 06:04AM
LPCN: TLANDO Launched
(Zacks Small Cap Research)
Aug-09-22 06:41AM
Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
(Simply Wall St.)
Aug-08-22 08:00AM
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022
(PR Newswire) -11.09%
Jul-11-22 08:00AM
FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment
(PR Newswire)
Jun-14-22 08:00AM
LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
(PR Newswire)
Jun-06-22 04:00PM
LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE
(PR Newswire)
May-20-22 07:12AM
LPCN: OLE Results
(Zacks Small Cap Research)
May-12-22 10:55AM
Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients
(Benzinga)
08:00AM
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
(PR Newswire)
May-10-22 11:30AM
LPCN: First Quarter 2022 Financial and Operational Results
(Zacks Small Cap Research)
May-09-22 08:00AM
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
(PR Newswire)
May-04-22 06:34AM
Shareholders in Lipocine (NASDAQ:LPCN) are in the red if they invested five years ago
(Simply Wall St.)
Apr-11-22 08:00AM
LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
(PR Newswire)
Mar-29-22 07:34PM
7 Undervalued Penny Stocks With Major Upside
(InvestorPlace) -20.33%
07:05AM
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO
(PR Newswire)
Mar-11-22 04:26AM
LPCN: 2021 Results
(Zacks Small Cap Research)
Mar-09-22 08:00AM
Lipocine Announces Financial Results for the Year Ended December 31, 2021
(PR Newswire) +6.38%
Mar-01-22 08:00AM
Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH
(PR Newswire)
Feb-25-22 07:42AM
Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?
(Simply Wall St.)
Feb-03-22 08:00AM
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®
(PR Newswire)
Jan-27-22 08:00AM
Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®
(PR Newswire)
Jan-05-22 08:00AM
Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
(PR Newswire)
Dec-22-21 08:00AM
LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS
(PR Newswire)
Nov-19-21 09:04AM
5 Penny Stocks Insiders Are Buying
(Benzinga) +7.34%
Nov-11-21 10:00AM
LPCN: Third Quarter Update
(Zacks Small Cap Research)
Nov-10-21 08:00AM
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021
(PR Newswire)
Nov-08-21 08:18AM
LPCN: Antares Agreement & NASH Fast Track Change the Calculus
(Zacks Small Cap Research) +7.14%
Nov-04-21 08:00AM
Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH
(PR Newswire) +6.31%
Nov-01-21 08:00AM
Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
(PR Newswire)
Oct-19-21 07:00AM
18 Stocks Moving in Tuesday's Pre-Market Session
(Benzinga)
Oct-18-21 12:15PM
Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
(Benzinga)
07:00AM
Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®
(PR Newswire)
Oct-05-21 08:00AM
Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
(PR Newswire)
Sep-28-21 08:00AM
Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
(PR Newswire)
Sep-20-21 08:00AM
Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference
(PR Newswire)
Sep-01-21 08:00AM
Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference
(PR Newswire)
Aug-31-21 05:43AM
LPCN: Liver Biopsy Results
(Zacks Small Cap Research)
Aug-25-21 06:30AM
Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study
(PR Newswire)
Aug-09-21 07:12AM
LPCN: New Candidate in Postpartum Depression
(Zacks Small Cap Research) +6.62%
Aug-05-21 08:00AM
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021
(PR Newswire)
Jul-15-21 09:00AM
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
(GlobeNewswire)
Jul-14-21 04:00PM
Lipocine Announces Settlement With Clarus Therapeutics
(PR Newswire)
Jul-06-21 08:00AM
Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
(PR Newswire)
Jun-23-21 08:00AM
Lipocine Announces Presentations at The International Liver Congress 2021 Digital Event
(PR Newswire)
Jun-16-21 08:00AM
Lipocine To Present At The Raymond James Human Health Innovation Conference
(PR Newswire)
Jun-14-21 08:00AM
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
(PR Newswire)
Jun-07-21 08:00AM
Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference
(PR Newswire)
May-27-21 05:31AM
LPCN: Summary Judgment Spurns Lipocine
(Zacks Small Cap Research)
May-26-21 12:44PM
Clarus Therapeutics Wins Jatenzo Patent Infringement Case Brought By Lipocine
(Benzinga) -11.68%
08:00AM
Summary Judgment Ruling in Patent Infringement Lawsuit
(PR Newswire)
May-25-21 08:32PM
Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment
(PR Newswire)
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel Mahesh V.CEO and PresidentMay 25 '23Buy5.038,70643,791107,418May 25 03:10 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

VIGL

Vigil Neuroscience Inc

Last Close
May 09 • 04:00PM ET
3.29
Dollar change
-0.49
Percentage change
-13.10 		%
VIGL Vigil Neuroscience Inc daily Stock Chart
Held by: VTI IWM VXF IWN VTWO IWC VTWV GSSC URTY UWM
IndexRUT P/E- EPS (ttm)-2.12 Insider Own33.04% Shs Outstand35.88M Perf Week19.89%
Market Cap123.45M Forward P/E- EPS next Y-1.95 Insider Trans0.02% Shs Float25.17M Perf Month2.98%
Income-82.78M PEG- EPS next Q-0.54 Inst Own33.92% Short Float3.66% Perf Quarter15.67%
Sales0.00M P/S- EPS this Y9.08% Inst Trans28.17% Short Ratio9.84 Perf Half Y-47.10%
Book/sh2.76 P/B1.19 EPS next Y-0.95% ROA-52.16% Short Interest0.92M Perf Year-65.20%
Cash/sh2.70 P/C1.21 EPS next 5Y- ROE-60.18% 52W Range2.50 - 11.11 Perf YTD-2.81%
Dividend Est.- P/FCF- EPS past 5Y- ROI-71.07% 52W High-70.43% Beta2.00
Dividend TTM- Quick Ratio12.38 Sales past 5Y0.00% Gross Margin- 52W Low31.40% ATR (14)0.33
Dividend Ex-Date- Current Ratio12.38 EPS Y/Y TTM0.09% Oper. Margin0.00% RSI (14)55.37 Volatility15.99% 10.90%
Employees69 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price16.75
Option/ShortNo / Yes LT Debt/Eq0.12 EPS Q/Q2.59% Payout- Rel Volume2.08 Prev Close3.78
Sales Surprise- EPS Surprise17.45% Sales Q/Q- EarningsMay 07 AMC Avg Volume93.63K Price3.29
SMA2012.85% SMA506.69% SMA200-26.95% Trades Volume194,996 Change-13.10%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Downgrade Morgan Stanley Equal-Weight → Underweight $13 → $4
Oct-18-23Initiated JMP Securities Mkt Outperform $23
Mar-31-23Initiated Mizuho Buy $15
Sep-16-22Initiated Wedbush Outperform $19
Aug-29-22Initiated H.C. Wainwright Buy $24
Feb-01-22Initiated Stifel Buy $24
Feb-01-22Initiated Morgan Stanley Equal-Weight $17
Feb-01-22Initiated Jefferies Buy $20
Feb-01-22Initiated Guggenheim Buy $23
May-08-24 07:40AM
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
(GlobeNewswire) +18.50%
May-07-24 10:55PM
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
(InvestorPlace) +10.38%
09:08PM
Vigil Neuroscience Inc (VIGL) Q1 2024 Earnings: Challenges Persist Amid Clinical Developments
(GuruFocus.com)
04:05PM
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
(GlobeNewswire)
Apr-17-24 04:05PM
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
(GlobeNewswire)
01:53PM Loading…
Mar-26-24 01:53PM
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
(InvestorPlace) -7.00%
07:05AM
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-20-24 07:05AM
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
(GlobeNewswire) +9.18%
Mar-13-24 07:05AM
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
(GlobeNewswire)
Mar-12-24 07:05AM
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
(GlobeNewswire) -5.99%
Mar-06-24 04:25PM
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
(GlobeNewswire)
Feb-29-24 04:05PM
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
(GlobeNewswire)
Feb-07-24 04:05PM
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
(GlobeNewswire)
Jan-03-24 04:30PM
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
(GlobeNewswire)
Nov-22-23 04:05PM
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
(GlobeNewswire) -9.17%
04:05PM Loading…
Nov-16-23 04:05PM
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
(GlobeNewswire)
Nov-07-23 07:05AM
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire) -9.34%
Oct-18-23 09:52AM
Arm initiated, SQM downgraded: Wall Street's top analyst calls
(The Fly)
Oct-17-23 07:05AM
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease
(GlobeNewswire) +6.65%
Oct-05-23 04:01PM
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
(GlobeNewswire)
Sep-26-23 07:05AM
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
(GlobeNewswire)
Sep-11-23 12:00PM
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
(GlobeNewswire)
Sep-08-23 04:05PM
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
(GlobeNewswire)
07:05AM
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
(GlobeNewswire)
Aug-08-23 07:05AM
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Aug-07-23 04:05PM
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
(GlobeNewswire) -8.33%
Jun-01-23 07:00AM
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
(GlobeNewswire)
May-10-23 07:00AM
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
May-09-23 07:00AM
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
(GlobeNewswire)
May-08-23 08:30AM
Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.)
07:08AM Loading…
07:08AM
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
(GlobeNewswire)
Mar-30-23 07:00AM
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
(GlobeNewswire)
Mar-22-23 07:00AM
Vigil Neuroscience to Present at Stifel 2023 CNS Days
(GlobeNewswire) +10.82%
Mar-21-23 07:00AM
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-02-23 04:00PM
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
(GlobeNewswire)
Jan-03-23 07:00AM
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-15-22 04:01PM
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
(GlobeNewswire)
Dec-14-22 04:01PM
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
(GlobeNewswire) +6.66%
Nov-29-22 05:23AM
We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business Growth
(Simply Wall St.)
Nov-28-22 07:00AM
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
(GlobeNewswire) +11.46%
Nov-10-22 07:00AM
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire) -23.86%
Nov-07-22 07:00AM
Vigil Neuroscience to Present at Upcoming Investor Conferences
(GlobeNewswire) +10.07%
Nov-02-22 12:43PM
Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease
(Benzinga) -12.04%
07:00AM
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
(GlobeNewswire)
Nov-01-22 07:00AM
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
(GlobeNewswire)
Oct-12-22 07:58AM
7 Short-Squeeze Stocks to Buy for Contrarian Investors
(InvestorPlace) +37.01%
Sep-14-22 09:55AM
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know
(Zacks)
Sep-01-22 07:00AM
Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference
(GlobeNewswire)
Aug-29-22 09:55AM
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%
(Zacks)
Aug-12-22 09:55AM
Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade
(Zacks) +8.34%
07:00AM
Vigil Neuroscience Announces $75 Million Private Placement Financing
(GlobeNewswire)
Aug-08-22 07:00AM
Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Aug-02-22 07:00AM
Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
(GlobeNewswire)
Aug-01-22 07:00AM
Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022
(GlobeNewswire)
Jul-28-22 07:00AM
Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.
(GlobeNewswire)
Jun-09-22 09:58AM
7 No-Brainer Biotech Stocks to Add to Your Buy List
(InvestorPlace)
Jun-07-22 07:00AM
Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia
(GlobeNewswire) +10.20%
Jun-01-22 07:00AM
Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference
(GlobeNewswire)
May-12-22 07:00AM
Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights
(GlobeNewswire)
Apr-20-22 07:00AM
Vigil Neuroscience Expands Leadership Team and Board of Directors
(GlobeNewswire)
Apr-08-22 12:33PM
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully
(Simply Wall St.)
Mar-25-22 06:30AM
Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
(GlobeNewswire) -6.94%
Mar-21-22 07:00AM
Vigil Neuroscience to Present at Stifel 2022 CNS Days
(GlobeNewswire) -24.37%
Mar-03-22 04:05PM
Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting
(GlobeNewswire)
Jan-27-22 01:46PM
Wall Street gyrations may thwart deal closings, IPO outlook
(American City Business Journals)
05:30AM
New Year, Fresh Stocks: 3 IPOs That Joined the Market in January
(Motley Fool)
Jan-11-22 04:01PM
Vigil Neuroscience Announces Closing of Initial Public Offering
(GlobeNewswire)
Jan-06-22 11:07PM
Vigil Neuroscience Announces Pricing of Initial Public Offering
(GlobeNewswire)
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Magovcevic-Liebisch IvanaPresident and CEONov 20 '23Buy3.754,00015,000207,687Nov 20 06:34 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.